Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT trial [Yahoo! Finance]
Cogent Biosciences, Inc. (COGT)
Last cogent biosciences, inc. earnings: 11/8 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.cogint.com/investor-relations
Company Research
Source: Yahoo! Finance
WALTHAM, Mass. and BOULDER, Colo., June 27, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced it has reached alignment with the U.S. Food and Drug Administration (FDA) on the Company's novel patient reported outcome measure, Mastocytosis Symptom Severity Daily Diary (MS2D2), for use in Part 2 of the registration-directed SUMMIT trial evaluating bezuclastinib in Nonadvanced Systemic Mastocytosis (NonAdvSM) patients. “We recently completed a positive discussion with the FDA on the use of MS2D2 in our SUMMIT trial for Nonadvanced Systemic Mastocytosis patients,” said Andrew Robbins, Cogent's President and Chief Executive Officer. “We remain on track to complete enrollment in SUMMIT Part 2 in the second quarter of 2025 and report top-line results by year-end 2025.” Cogent's questionnaire, MS2D2, asks patients about their symptoms at baseline and measures
Show less
Read more
Impact Snapshot
Event Time:
COGT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
COGT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
COGT alerts
High impacting Cogent Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
COGT
News
- Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting [Yahoo! Finance]Yahoo! Finance
- Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.MarketBeat
- Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT trialGlobeNewswire
- Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $18.00 price target on the stock.MarketBeat
- Cogent Biosciences, Inc. (NASDAQ: COGT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.MarketBeat
COGT
Earnings
- 8/8/23 - Miss
COGT
Sec Filings
- 6/27/24 - Form 8-K
- 6/13/24 - Form 4
- 6/13/24 - Form 4
- COGT's page on the SEC website